Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting - PubMed
5 hours ago
- #Incretin Mimetics
- #Dose-Escalation
- #Type 2 Diabetes
- Dose-escalation regimens for incretin mimetics (GLP-1 receptor agonists and tirzepatide) in Type 2 diabetes help reduce gastrointestinal adverse events like nausea and vomiting.
- Tolerance for nausea and vomiting is higher in Phase 3 trials (with dose escalation) compared to Phase 1 trials (no or short dose escalation), as indicated by the ED50 ratio (Phase 3/Phase 1).
- Longer drug escalation periods and more dose-escalation steps are associated with greater tolerance for nausea and vomiting.
- Higher tolerance allows for the use of higher doses, which are linked to greater therapeutic effectiveness in reducing HbA1c and body weight.
- Optimized dose-escalation regimens can improve patient adherence and treatment outcomes for incretin-based medications.